Fidelity Disruptive Medicine Fund
Data updated: 2023-08-03
C000219007 — Fidelity Disruptive Medicine Fund. Developed ex-US Growth Thematic Equity · $43.22M AUM. Holdings, fees, performance and SEC filings.
C000219007 Fund Overview
Fidelity Disruptive Medicine Fund is a US mutual fund managed by Fidelity Summer Street Trust, categorised as Developed ex-US Growth Thematic Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Summer Street Trust
- Category: Developed ex-US Growth Thematic Equity
- Assets under management: $43.22M
- 1-year return: -7.3%
- SEC CIK: 0000225322
- SEC series ID: S000067934
- Share class ID: C000219007
C000219007 Investment Objective and Strategy
Fidelity Disruptive Medicine Fund describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Fidelity Summer Street Trust.
Investment objective
The fund seeks long-term growth of capital.
Principal investment strategy
"Normally investing at least 80% of assets in securities of disruptive medicine companies. Fidelity?s disruptive strategies seek to identify innovative developments that could signal new directions for delivering products and services to customers. Generally, these companies have or are developing new or unconventional ways of doing business that could disrupt and displace incumbents over time. This may include creating, providing, or contributing to new or expanded business models, value networks, pricing, and delivery of products and services. Companies within the disruptive medicine theme include but are not limited to those companies that, in the Adviser?s opinion, are engaged in robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, advanced diagnostics and consumer wellness.
In pursuing this investment theme, the fund may invest in companies in any economic sector. Although the fund may invest across economic sectors, the fund concentrates its investments in the health care industries. Normally investing primarily in equity securities. Using fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments with quantitative portfolio construction. Investing in either ""growth"" stocks or ""value"" stocks or both. Investing in securities of domestic and foreign issuers."
C000219007 Performance
Total returns for C000219007 (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| 1 year | -7.3% |
| 3 years (annualised) | 2.4% |
C000219007 Risk Information
Risk metrics for C000219007, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 20.9%
C000219007 Costs and Fees
C000219007 costs about $50 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.50%
- Gross expense ratio: 0.50%
- Portfolio turnover: 47%
- Brokerage commissions: 2.65 bps of average net assets (SEC N-CEN)
C000219007 Cashflows
Over the 12 months to 2023-05, Fidelity Disruptive Medicine Fund had net outflows of $13.85M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2023-05 | −$371.35K |
| 2023-04 | $1.29M |
| 2023-03 | −$876.60K |
| 2023-02 | −$892.48K |
| 2023-01 | −$912.02K |
| 2022-12 | −$2.78M |
C000219007 Debt Constituents
No individual debt constituents are reported in Fidelity Disruptive Medicine Fund's latest SEC N-PORT filing.
C000219007 Prospectus and SEC Filings
Official Fidelity Disruptive Medicine Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2022-07-26
- Prospectus (485BPOS) — filed 2021-07-27
- Prospectus supplement (497) — filed 2021-10-07
- Portfolio holdings (N-PORT) — filed 2023-07-26
- Portfolio holdings (N-PORT) — filed 2023-04-27
- Portfolio holdings (N-PORT) — filed 2023-01-26
- Annual census (N-CEN) — filed 2023-08-03
- Annual census (N-CEN) — filed 2022-08-08
Related Funds
Other Developed ex-US Growth Thematic Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.